Psilocybin-facilitated Treatment for Chronic Pain (NCT05068791) | Clinical Trial Compass
RecruitingEarly Phase 1
Psilocybin-facilitated Treatment for Chronic Pain
United States30 participantsStarted 2023-11-01
Plain-language summary
The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia. Investigators will assess the impact of psilocybin-facilitated treatment on pain, fatigue, and other fibromyalgia symptoms, in addition to the level of functioning and quality of life. Investigators will also evaluate potential mediators of treatment (e.g., treatment expectations, pain characteristics, personality, beliefs/cognitions, emotions). Investigators hypothesize psilocybin treatment will significantly reduce symptom severity in fibromyalgia patients.
Who can participate
Age range25 Years – 65 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Female age 25-65;
✓. Widespread musculoskeletal pain for ≥12 months;
✓. Symptoms meeting the American College of Rheumatology (ACR) 2016 revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria;
✓. Participant completes daily report during baseline period (at least 80% completion rate);
✓. Able to attend UAB for all scheduled appointments;
✓. Ability to read/write in English;
✓. No prior hallucinogen use or it will have been at least 3 years since last use of a hallucinogen;
✓. Availability of a friend or family member into whose care the participant can be released (a key responsibility includes driving participants home) following their drug administration session;
Exclusion criteria
✕. Males;
✕
What they're measuring
1
Change in daily self-reported pain severity
Timeframe: through study completion, up to 13 weeks
✕. Regular use of any anti-inflammatory medication (e.g., aspirin, ibuprofen, naproxen);
✕. Use of blood thinning medication;
✕. Use of tricyclic antidepressants, lithium, SSRIs, MAOIs, St. John's Wort, 5-hydroxytryptophan (5-HT), haloperidol, or other antipsychotic medications, mood stabilizers, or medications with serotonin activity;
✕. Daily consumption of grapefruit juice;
✕. Febrile illness or use of antibiotics in the 4 weeks before study commencement;
✕. Planned surgery or procedures during the study period, or operated on in the 4 weeks prior to study commencement;